Type 2 diabetes

Vounzoulaki, E., Miksza, J. K., Zaccardi, F., Tan, B. K., Davies, M. J., Khunti, K., & Gillies, C. L. (2024). Association of ethnicity and socioeconomic status with health outcomes in women with gestational diabetes: Clinical practice research datalink cohort study. Diabetes Metab Syndr, 18, 103010. http://doi.org/10.1016/j.dsx.2024.103010
Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.16039
Carey, I. M., Critchley, J. A., U, A. R. C., Cook, D. G., DeWilde, S., Limb, E. S., et al. (2024). Effects of long-term HbA1c variability on serious infection risks in patients with type 2 diabetes and the influence of age, sex and ethnicity: A cohort study of primary care data. Diabetes Res Clin Pract, 111641. http://doi.org/10.1016/j.diabres.2024.111641
Morgan, C. L., Durand, A., McCormack, T., Hughes, E., Berni, T. R., & Lahoz, R. (2023). Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the CPRD. Bmj Open, 13, e064541. http://doi.org/10.1136/bmjopen-2022-064541
Davies, M., Alibegovic, A. C., Anil, G., Braae, U. C., Jensen, A. B., & Nordsborg, R. B. (2023). Real-world study of the concomitant use of biphasic insulin as part 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes. Diabet Med, e15267. http://doi.org/10.1111/dme.15267
Davies, M. J., Alibegovic, A. C., Kelkar, P., Braae, U. C., & Jensen, A. B. (2023). Glycaemic control and weight outcomes after adding or switching to biphasic insulin aspart 30/70 in people with type 2 diabetes mellitus previously treated with basal-bolus insulin in UK clinical practice. Diabetes Obes Metab. http://doi.org/10.1111/dom.15278
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab. http://doi.org/10.1111/dom.15220
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
Zheng, B., Su, B., Ahmadi-Abhari, S., Kapogiannis, D., Tzoulaki, I., Riboli, E., & Middleton, L. (2023). Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment. Alzheimers Dement. http://doi.org/10.1002/alz.13349
Raslan, A. S., Quint, J. K., & Cook, S. (2023). All-Cause, Cardiovascular and Respiratory Mortality in People with Type 2 Diabetes and Chronic Obstructive Pulmonary Disease (COPD) in England: A Cohort Study Using the Clinical Practice Research Datalink (CPRD). Int J Chron Obstruct Pulmon Dis, 18, 1207-1218. http://doi.org/10.2147/copd.s407085